These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 24452757)
21. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928 [TBL] [Abstract][Full Text] [Related]
22. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462 [TBL] [Abstract][Full Text] [Related]
23. Pancreatic NETs: where do we stand now? Faivre S; Castellano D; Strosberg J; González E; Salazar R Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757 [TBL] [Abstract][Full Text] [Related]
25. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Mateo J; Heymach JV; Zurita AJ Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658 [TBL] [Abstract][Full Text] [Related]
26. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N; Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872 [TBL] [Abstract][Full Text] [Related]
27. Targeted agents in treatment of neuroendocrine tumors of pancreas. Karampelas IN; Syrigos KN; Saif MW JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341 [TBL] [Abstract][Full Text] [Related]
28. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors. Capdevila J; Tabernero J Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573 [TBL] [Abstract][Full Text] [Related]
29. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165 [TBL] [Abstract][Full Text] [Related]
31. Advances in the treatment of pancreatic neuroendocrine tumours. Gao F; Visvardis EE; Sita-Lumsden A; Waxman J QJM; 2012 Sep; 105(9):819-22. PubMed ID: 22383691 [TBL] [Abstract][Full Text] [Related]
32. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy. Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266 [TBL] [Abstract][Full Text] [Related]